image credit- shutterstock
Ahmedabad-based Zydus Lifesciences has entered into exclusive negotiations to purchase from PAI Partners and Amplitude Surgical’s management, as well as two minority shareholders, 85.6% of the share capital of Amplitude Surgical, at a price of €6.25 per Amplitude Surgical share.
The acquisition price represents a 80.6% premium over the last closing price as on 10/03/2025 and premia of 88.2% and 92.2% over the 3-month and 6-month volume-weighted average price of Amplitude Surgical respectively.
Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies. The company provides numerous value-added innovations to best meet the needs of patients, surgeons and healthcare facilities. This includes the design and development of knee and hip prostheses, which are implanted in place of damaged or worn-out joints.
Supported by PAI Partners, through its Mid-Market Fund, Amplitude Surgical has experienced significant growth over the last four years, driven by new product development, international growth, investments in manufacturing capabilities and R&D.
In fiscal year ended June 30, 2024, Amplitude Surgical generated sales of €106 million and EBITDA of €27.1 million on a consolidated basis under IFRS. For the 6 months ended December 31, 2024, Amplitude Surgical’s consolidated sales amounted to €51.5 million (a growth of 5% Y-o-Y at current exchange rates) with an EBITDA margin of approximately 25.4% (unaudited figures).
Zydus MedTech is focusing on high quality products and solutions for patients with cutting-edge research and innovation around design and engineering. The focus will also be on state-of-the-art manufacturing capabilities that will enable high quality solutions supported by a specialist team. The business currently markets interventional cardiology products.
